PCBD1

Across TCGA pan-cancer cohorts, PCBD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCBD1 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PCBD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCBD1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where PCBD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.673	0.873	.003	14	view →
LSCC	DFS	Median	III,IV	0.846	0.411	.035	4	view →
PDAC	OS	Median	IV	0.395	0.937	.026	3	view →
LUAD	OS	Median	III,IV	0.611	0.995	.022	3	view →
GBM	DFS	Quartile	All	0.433	0.228	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCBD1–HNSC (DFS)

Open the HNSC breakdown →